Alzamend Neuro Inc. is a clinical-stage biopharmaceutical company headquartered in Atlanta, Georgia, focused on developing novel treatments for neurodegenerative and psychiatric disorders. The company's primary pipeline consists of two therapeutic drug candidates: AL001, a patented ionic cocrystal technology that delivers lithium combined with proline and salicylate for treating Alzheimer's disease, bipolar disorder, major depressive disorder, and post-traumatic stress disorder; and ALZN002, a cell-based therapeutic vaccine designed to restore the immune system's ability to combat Alzheimer's disease. Both product candidates are licensed from the University of South Florida Research Foundation under exclusive worldwide licenses. AL001 is currently in clinical development, with recent Phase II trials demonstrating bioequivalence to standard lithium carbonate while showing numerically superior lithium delivery to the brain. The company collaborates with Massachusetts General Hospital as its contract research organization to advance clinical trials across multiple therapeutic indications affecting over 600 million people globally.